The objective of this study was to fabricate of a bioactive composite scaffold for drug delivery aiming that the innovated tissue engineering scaffold be bifunctional. That innovated biocomposite scaffold should offer both good bioactivity to enhance cell adhesion, differentiation and proliferation as well as antimicrobial activity as a local drug delivery system to prevent bone infections and osteomyelitis at the surgical site of scaffold implantation. The bioactive composite scaffolds was fabricated from the chitosan polymer (which offered a biocompatible and biodegradable polycationic matrix) and the 46S6 bioactive glass (which provided bioactivity, improved the compressive strength and hindered the rapid ex vivo biodegradation of the prepared scaffold in order to enhance bone regeneration in stress bearing areas) and finally the GS drug as local antibiotic (which is prophylactic against the surgery accompanied sepsis). Evidently, four types of chitosan-based (C, 1C:1G, 1C:2G and 2C:1G) scaffolds were prepared and in each five scaffolds (n=5) were used.Then, physicochemical characterization of all elaborated scaffold compositions were done; SEM analysis, FTIR spectroscopy, XRD analysis, ICP-OES, mercury intrusion porosimetry, ex-vivo biodegradation in SBF and compressive strength test, which analyzed the microstructure, the functional groups, the crystalline phases, the ion (Ca2+, P3- and Si4+) concentrations, the porosity pattern, the rate of biodegradation and mechanical properties. Fortunately, the 1C:2G biocomposite scaffold composition revealed relatively best results of physicochemical analyses compared to all scaffold compositions; average pore size 0.0923 µm, porosity % of 68.62 ± 8.52% and pore interconnectivity and good mean compressive strength of (9.30 ± 1.45 MPa and 9.32 ± 1.67 MPa before and after drug loading with 30mg/ml GS by immersion method). The selected 1C:2G biocomposite scaffold had the least percentage of porosity (60.84%), the least weight loss percentage of all scaffold groups after one month of immersion in SBF (70.6%) and it has a relatively high compressive strength of ~7.38MPa before GS drug loading by immersion and ~ 9.31MPa after GS drug loading. Moreover; the 1C:2G composite scaffold contained the highest percentage of the 46S6 bioactive glass, which rendered it the most bioactive of all scaffold groups. This was confirmed by the CHA layer thickness. Therefore; the 30mg/ml GS loaded 1C:2G composite scaffold showed the best GS release results of all scaffold groups by UV spectroscopy. Furthermore; the antimicrobial tests (Staphylococcus aureus: agar diffusion assay and MTT assay system) that were performed for the drug loaded scaffolds revealed that the GS loaded 1C:2G composite scaffold had the most antimicrobial activity and drug sustainability of all GS loaded scaffold groups. The ex-vivo study succeeded for fabrication of a bifunctional biocomposite scaffold as drug delivery device for application in bone tissue engineering purposes.